|1.||Catania, Anna: 2 articles (03/2012 - 01/2010)|
|2.||Gatti, Stefano: 2 articles (03/2012 - 01/2010)|
|3.||Carlin, Andrea: 2 articles (03/2012 - 01/2010)|
|4.||Leonardi, Patrizia: 2 articles (03/2012 - 01/2010)|
|5.||Sordi, Andrea: 2 articles (03/2012 - 01/2010)|
|6.||Lonati, Caterina: 2 articles (03/2012 - 01/2010)|
|7.||Vincenot, Amélie: 1 article (02/2015)|
|8.||Chezal, Jean-Michel: 1 article (02/2015)|
|9.||Miladi, Imen: 1 article (02/2015)|
|10.||Bouchon, Bernadette: 1 article (02/2015)|
01/01/2008 - "The in vivo affinity and specificity of the radioconjugate to MC1R were demonstrated by receptor-blocking studies with the potent NDP-MSH agonist (63.5% reduction in tumor uptake at 4 h p.i.)."
02/01/2009 - "This resulted in enhanced extravasation of NDP-MSH-PEG-HAuNS from tumor blood vessels and their dispersion into tumor matrix compared with nonspecific PEGylated HAuNS. "
02/01/2009 - "The biodistribution of NDP-MSH-PEG-HAuNS was assessed at 4 hours post i.v. injection in tumor-bearing nude mice. "
12/01/2002 - "Therefore, (111)In-DOTA-MSH(oct) displayed higher uptake ratios of tumor to nontarget tissue (e.g., tumor-to-bone ratio 4 h after injection was 4.9 for (111)In-DOTA-NDP-MSH and 53.9 for (111)In-DOTA-MSH(oct)). "
02/12/2015 - "Then, radiolabeled [ (125) I]/[ (18) F]TFIB was used to tag tumor-targeting peptides (i.e., PEG3[c(RGDyK)]2 and NDP-MSH targeting αvβ3 integrin and MC1R receptors, respectively) in mild conditions and with good radiochemical yields (47-83% d.c.) and purities (>99%). "
|3.||Melanoma (Melanoma, Malignant)
01/01/2013 - "Our new melanoma cell lines were BRAF mutated in hetero- and homozygosis, even with a wild type MC1R, and unresponsive to NDP-MSH treatment. "
02/01/2009 - "NDP-MSH-PEG-HAuNS have the potentials to mediate targeted photothermal ablation of melanoma."
06/01/1990 - "In melanoma specimens from 11 patients, 3 showed high levels of specific binding, 5 showed low levels, and in 3 patients specific binding of [125I]NDP-MSH was not detectable. "
02/01/2009 - "The intracellular uptake of the NDP-MSH-conjugated PEGylated HAuNS (NDP-MSH-PEG-HAuNS) and the distribution of beta-arrestin were examined in murine B16/F10 melanoma cells. "
05/01/1992 - "In both mouse and human melanoma tissues, concentration-response relationships for DAB389-MSH-mediated inhibition of 125I-NDP-MSH binding were parallel, and its maximal effects were comparable in magnitude, to those of NDP-MSH and alpha-MSH. "
|4.||Body Weight (Weight, Body)
09/01/2012 - "In the next study, a subthreshold dose of β-EP was injected together with Nle(4), d-Phe(7) (NDP)-MSH after a 16-h fast, and the negative effects of NDP-MSH on refeeding and body weight gain were partially reversed. "
04/22/2005 - "Acute and chronic intracerebroventricular administration of several different analogues of alpha-MSH, such as alpha-MSH, NDP-MSH, alpha-MSH-ND, [Gln(6)]alpha-MSH-ND, and [Lys(6)]alpha-MSH-ND, which were substituted in the position of His(6) with Gln and Lys, and cyclic16k-MSH to C57J/BL6 mice resulted in a significant inhibition of both time course food intake and body weight gain, compared to the saline-administered control. "
|6.||Melanocyte-Stimulating Hormones (MSH)
|7.||Adrenergic Receptors (Adrenergic Receptor)
|8.||Polyethylene Glycols (Polyethylene Glycol)
|10.||Immunoglobulin G (IgG)
|1.||Dilatation and Curettage (D&C)